Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

0
29
Arcutis Biotherapeutics, Inc. announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE topical foam 0.3% for the treatment of seborrheic dermatitis in patients nine years of age and older.
[Arcutis Biotherapeutics, Inc.]
Press Release